Prazer Targets The Undruggable With Dual-Pathway TPD Platform
Prazer CEO talks to Scrip how the Korean biotech is advancing its proprietary TPD platform, designed to target both proteasome and lysosomal degradation pathways to address targets inaccessible to conventional approaches.
Scrip - July 8, 2026

MDUFA VI Draft Commitment Letter Includes Faster Pre-Submission Lane, Expanded AI Commitments
FDA's MDUFA VI draft commitment letter introduces a faster pre-submission lane, introduction meetings for De Novo sponsors, and expanded AI and digital health commitments — while holding PMA timelines steady and transitioning the TAP program from pilot to permanent.
Medtech Insight - July 7, 2026

FDA Electronic Labeling Proposal Could Reshape Medical Device Instructions For Use
The FDA is proposing a rule that would allow device manufacturers to replace paper instructions for use with electronic labels. The proposal — part of the federal 2026 Unified Agenda — targets an NPRM publication in November 2026 and is expected to reduce regulatory burden on the industry.
Medtech Insight - July 7, 2026

EU Tests Drug-Diagnostic Partnerships In Unified Pathway Pilot
An ongoing pilot will test whether a single pathway for combined drug and diagnostic/device studies works with products developed by separate companies.
Medtech Insight - July 7, 2026

Alcon Bets Up To $200m On Tunable IOLs In RxSight Collaboration
Alcon will license RxSight's light-adjustable technology in a non-exclusive deal worth up to $200m to co-develop tunable presbyopia-correcting IOLs, paying $60m upfront.
Medtech Insight - July 7, 2026

Q&A With Unilever Senior VP On US Innovation Center
HBW Insight chats with Leo Aquino, SVP R&D, Unilever North America, on the significance of the company's new innovation center in New Haven, Conn.
HBW Insight - July 8, 2026

Apotex And Cumberland Deal Reaches Completion
Canadian pharma giant Apotex has successfully completed its acquisition of Cumberland Pharmaceutical’s US branded businesses.
Generics Bulletin - July 7, 2026

Towa Adds Tanabe Capacity To Stabilize Off-Patent Supply
Towa’s deal for Tanabe Pharma Factory adds owned capacity, 35 product approvals and originator know-how, extending a wider strategy to shore up Japan’s off-patent medicines supply through acquisitions, outsourcing and backup production.
Generics Bulletin - July 7, 2026

Alvotech Seeks Launch Momentum From Renewed FDA Push
After betting early on streamlined biosimilar development and first-wave assets, Alvotech is now trying to turn foresight into approvals, launches and access, Róbert Wessman says in an exclusive interview with Generics Bulletin.
Generics Bulletin - July 7, 2026

Cancer Drug Suppliers In Limelight As Oxaliplatin Added To US List Of Shortages
Oncology drug suppliers like Fresenius Kabi, Sandoz, Teva, Dr. Reddy’s and Aurobindo are in the spotlight as they hold keys to solving a deepening cancer drugs shortage crisis in US, EU, Australia, Canada and India, amid originator brand discontinuations and structural issues.
Generics Bulletin - July 7, 2026

Execs On The Move: June 2026
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
In Vivo - July 7, 2026

Inside AbbVie’s Biology-First ADC Strategy
As the antibody-drug conjugate field expands rapidly, AbbVie has quietly assembled one of oncology's largest ADC pipelines while pursuing a strategy centred on matching treatments to patient biology.
In Vivo - July 7, 2026